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Background: RANTES is a CC-type chemokine protein that acts as a 
chemoattractant for several kinds of leukocytes, playing an important pro- 
inflammatory role. Entry of human immunodeficiency virus-l (HIV-i) into cells 
depends on the chemokine receptor CCR5. RANTES binds CCR5 and inhibits 
HIV-1 entry into peripheral blood cells. Interaction with chemokine receptors 
involves a distinct set of residues at the amino terminus of RANTES. This 
finding was utilized in the development of a chemically modified 
aminooxypentane derivative of RANTES, AOP-RANTES, that was originally 
produced from the recombinant protein using semisynthetic methods. 
Results: AOP-RANTES has been produced by a novel total chemical synthesis 
that provides efficient, direct access to large amounts of this anti-HIV protein 
analog. The crystal structure of chemically synthesized AOP-RANTES has been 
solved and refined at 1.6A resolution. The protein is a dimer, with the amino- 
terminal pentane oxime moiety clearly defined. 
Conclusions: Total chemical synthesis of AOP-RANTES provides a convenient 
method of producing the multi-milligram quantities of this protein needed to 
investigate the molecular basis of receptor binding and antiviral activity. This 
work provides the first truly high-resolution structure of a RANTES protein, 
although the structure of RANTES was known from previous nuclear magnetic 
resonance (NMR) determinations. 
Introduction 
Chemokines are a diverse family of numerous small 
(8-10 kDa) proteins that mediate a wide range of inflam- 
matory responses in humans. These proteins are secreted at 
the site of injury by many types of tissue cells, including 
platelets, and frequently act as chemoattractants for a 
variety of blood cells. Chemokines display a conserved 
pattern of cysteine residues and are categorized into two 
major subgroups, CC and CXC, depending on the sequence 
of two key cysteine residues near the amino terminus of 
the proteins. RANTES (regulated on activation normal 
T cell expressed and secreted) is a 9 kDa CC chemokine 
protein that acts as a chemoattractant and activating agent 
for a broad range of immune system cells, such as mono- 
cytes, T lymphocytes and eosinophils, but not neutrophils 
[l]. It is suggested to play a role in certain inflammatory 
disorders, such as endotoxemia [Z] and rheumatoid arthri- 
tis [3]. RANTES binds to and signals through a number 
of chemokine receptors, namely CCRl [4-S], CCR3 [7], 
CCR4 [9] and CCR.5 [lo-121. Other CC chemokines, such 
as MIP-la and IMIP-~~, can compete for binding to each of 
the RANTES receptors. This competition is not surprising, 
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as their amino-acid sequences and tertiary structures are 
quite similar. Because cells possess more than one type of 
chemokine receptor, a complicated modulation of effects 
can arise by the cross-networking of receptors and chemo- 
kine ligand interactions. 
The chemokine receptor CCR.5 is a seven-transmembrane 
G-protein-coupled receptor that has been identified as the 
principal coreceptor for human immunodeficiency virus-l 
(HIV-l) entry into peripheral blood cells. Because CCRS 
acts as a coreceptor for HIV-1 uptake into mononuclear 
cells, the binding of RANTES to CCRS and the subse- 
quent internalization of the chemokine-receptor complex 
can block the initial infection by the virus [13,14]. Recently, 
it was shown that chemical modification of R4NTES at the 
amino terminus produced a potent antagonist of HIV-I 
entry into macrophages and other peripheral blood lympho- 
cytes mediated by CCR5 [15]. In that work. based on the 
observation that Met-RANTES (a derivative of RANTES 
in which a methionine residue precedes the normal amino- 
acid sequence) acted as a receptor antagonist, the protein 
AOP-RAN’rES was prepared from recombinantly expressed 
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Synthetic scheme for the preparation of AOP- 
RANTES by means of native chemical ligation 
of ttnprotected peptide In aqueous solution. 
The two shaded residues show the native 
chemical ligation site at Lys33-Cys34. Single- 
letter amino-acid code is used. 
RANTES by semisynthetic methods [16]. Mild periodate 
oxidation of the l-amino 2-01 moiety in the amino-terminal 
serine of the folded disulfide-containing RANTES protein 
molecule generated a glyoxal functionality; subsequent 
chemoselective reaction with aminooxypentane was used 
to form an oxime bond, generating the modified protein 
[n-pentyl-O-N = CHCO][~~~Serl]RANTES [1.5]. 
Here, we report a novel total chemical synthesis that pro- 
vides more efficient, direct access to large amounts of AOP- 
RANTES. In a retrosynthetic sense, AOP-RANTES was 
first envisioned as the unfolded polypeptide chain, which 
was, in turn, divided into an amino-terminal segment, the 
peptide AOP-RANTES (Z-33)-ol-thioester and a carboxy- 
terminal segment, RANTES (34-68). This approach allowed 
us to use native chemical ligation [17] to join these 
unprotected peptide segments at the central Lys33-Cys34 
sequence by reaction in aqueous solution at neutral pH 
(Figure 1). ,4fter preliminary experimentation, we devised a 
practical route for the incorporation of the AOP moiety, and 
the amino-terminal segment was further retrosynthetically 
divided into the peptide moiety comprising residues 2-33 
and the oxime-containing moiety (compound 1, Figure 1 j to 
provide a practical route to the desired protein molecule. 
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We used the resulting high-purity chemically synthesized 
AOP-RANTES protein for X-ray crystallography to deter- 
mine the three-dimensional structure of the molecule. 
The structure of recombinant RANTES in solution wds 
previously determined independently by two groups [l&19], 
but many questions about the structure were left unan- 
swered in these medium-quality nuclear magnetic reso- 
nance (NMR) studies. Specifically, the positions of the 
first five residues of the amino terminus and several of the 
residues at the carboxyl terminus were not defined at all, 
and the orientation of the two monomers within the dimcr 
was not well defined. In this paper, we report the use of X- 
ray crystallography to reveal the structure of a RANTES 
protein in much greater detail. The majority of the struc- 
ture remains similar to the NhlR models, as shown by D 
comparison to the high-resolution (1.6 A) crystal structure 
of AOP-RANTES described here. Furthermore, in elec- 
tron-density maps of the crystalline protein, the amino ter- 
minus of AOP-RANTES is clearly bound in a hydrophobic 
depression on the surface of the protein molecule. 
Results and discussion 
Chemical synthesis of the AOP-RANTES (2-68) polypeptide 
Synthesis of the peptide segments was accomplished in a 
straightforward manner using stepwise solid phase peptide 
synthesis (SPPS) [ZO]. The amino-terminal segment AOP- 
RANTES (Z-3.3)-a-thioester was prepared on a thioester- 
generating resin [Zl], using highly optimized Rot chemistry 
SPPS [ZZ]. At the last step in the synthesis of this segment, 
the modified amino terminus was generated by on-resin 
reaction of RANTES (Z-33) with compound 1 preacti- 
vated as the HOAt (l-hydroxy-7-azabenzotriazole) ester 
to give AOP-RANTES (Z-33)-a-thioester-resin. This reac- 
tion proceeded quantitatively, with none of the starting 
material RANTES (Z-33) detected by electrospray ion- 
ization-mass spectrometry (ESI-MS) after cleavage and 
deprotection. Several other routes for the incorporation of 
the oxime moiety were also explored, but with unsatisfac- 
tory results. Synthesis of the carboxy-terminal peptide 
segment RANTES (34-68) was carried out according to 
published protocols [Z]. Both peptide segments were 
synthesized on a 0.25 mmol scale of starting aminoacyl- 
resin. Following deprotection and cleavage (anhydrous 
hydrogen fluoride, p-cresol (5% v/v). O”C, 1 h), the pep- 
tides were purified using reverse-phase high-pressure liquid 
chromatography (RI’-HPLC) in good yield: greater than 
100 mg quantities of each purified segment were obtained 
from a single synthesis. 
AOP-RANTES (Z-33)~a-thioester (25 pmol) and RANTES 
(34-68) (27 pmol) were reacted at pH 7 in aqueous buffer 
containing 6 IVl GuHCI as a chaotropic agent. Thiopheno] 
(0.5% v/v) was added to the ligation mixture to ensure that 
cysteine residues were present in the reduced form and to 
catalyze the reversal of unproductive thioester formation 
Figure 2 
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Native chemical ligation of AOP-RANTES (2-33)wthioester and 
RANTES (34-68) in aqueous solution at pH 7. The ligation reaction i: 
shown at: (a) 0 and (b) 16 h. The ligation reaction was monitored by 
injecting 1 ~1 aliquots of the ligation solution on a CJ RP-HPLC 
column wiih a gradient of 5-65% acetonitrile versus water contalmng 
0.1% TFA, over 30 min. Detection was at 214 nm. (c) Characterization 
of the puriiied ligation product. Analytical RP-HPLC chromatogram 
with an inset showing ESI-MS of AOP-RANTES (2.-68)-[(SH,)]: 
observed mass, 7904.5 + 0.6 Da; calculated mass (average isotope 
composition), 7905.1 Da. 
[23]. The amino-terminal segment, AOP-RANTES (2-33)- 
a-thioester, was added in portions to minimize insolubility 
due to aggregation and consequent poor reaction. The 
ligation r-action was monitored using analytical RP-HPLC 
and ESI-MS and was shown to have gonl: to completion 
after 16 h (Figure Zb). No significant side reactions were 
observed for ligation using this functionalized peptidyl- 
lysine-a-rhioester (Figure 2). Purification of the ligation 
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Figure 3 
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chromatogram of the total crude folding products obtained. For the major 
Foldingldisulfide formation. The purified polypeptide AOP-RANTES 
product, the retention time is 1.22 min earlier than the reduced 
(2-68)[(SH)J was stirred overnight at pH 8 in 2 M GuHCl in the 
polypeptide, which is consistent with folding/disulfide formation. 
(b) Characterization of purified synthetic AOP-RANTES. Analytical 
presence of 8 mM cysteine and 1 mM cystine. (a) Analytical RP-HPLC 
synthetic protein AOPRANTES (two-dimensional TOCSY experiment 
performed at 600 MHz). The data show that a single conformation 
predominates and are consistent with the canonical chemokine fold. The 
RP-HPLC chromatogram with an inset showing ES&MS of AOP- 
annotation.3 refer to the backbone assignments made on this sample. 
RANTES: observed mass, 790 1.2 f 0 6 Da; calculated mass (average 
isotope composition), 7091 .15 Da. (c) ‘H NMR measurements on the 
solution by semipreparative RP-HPLC gave the ligated 
polypeptide product AOP-RANTES (57.8 mg, 7.3 pmol, 
30% recovered yield based on peptide segments). The yield 
is significantly reduced compared with similar chemical- 
ligation synthesis of native RANTES, which may be attrib- 
uted to reduced recovery in the reversed-phase purification 
due to the increased hydrophobicity of the AOP-poly- 
peptide. The reduced polypeptide was characterized by 
ESI-MS (observed mass, 7904.5 ? 0.6 Da; calculated mass, 
average isotope composition, 7905.2 Da). 
Folding and characterization 
Folding and disulfide formation was carried out at pH 8 by 
dissolving the purified polypeptide AOP-RANTES (2-68)- 
[(SH),] in an aqueous buffer of 2 M GuHCI, 100 mM Tris 
containing 8 mM cysteine and 1 mll/I cystine. After gentle 
stirring overnight, near-quantitative folding was obtained 
(Figure 3a). Compared with the reduced polypeptide chain, 
the folded product gave a sharp peak that eluted earlier on 
an analyt-ical RP-HPLC Icolumn, consistent with the for- 
mation of a folded disulfide-cross-linked protein. In com- 
parison with the reduced polypeptide, using ESI-MS, this 
product showed a loss of 3.3 f  1.2 mass units, consistent 
with the formation of the expected two disulfides in the 
folded protein molecule. Purification by semipreparative 
RP-HPLC produced the protein AOP-RANTES (32 mg, 
4.0 pmol, 55% yield based on unfolded polypeptide, 16% 
yield based on peptide s,egments) in greater than 95% 
purity (as determined by analytical RP-HPLC; 
Figure 3b). The product was characterized further using 
ESI-MS (observed mass 7901.2 f  0.6 Da; calculated mass, 
average isotope composition, 7901.2 Da). 
The correct formation of the protein tertiary structure was 
confirmed using NMR spectroscopy. Under the conditions 
used (pH 3.7, -1 mM protein), native RANTES is mainly a 
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dimer [18]. As shown in Figure 312, it Was possible to assign, 
in most cases, single cross-peaks in the total correlation 
spectroscopy (TOCSY) spectrum to particular residues of 
AOP-RANTES, demonstrating that a single conformation 
predominates. Some evidence of a second conformation is 
present, but this is also seen for the native RANTES and 
arises from the presence of the monomeric form at low 
concentration. Moreover, the chemical shifts of assigned 
residues are nearly identical to those of the equivalent 
residues in native RANTES, which demonstrates that 
both proteins have very similar structures. The evidence for 
correct formation of the protein tertiary structure was 
further provided by the crystal structure (see below) and by 
the ability of synthetic AOP-RANTES to completely 
inhibit CCRS-dependent fusion of HIV-l M-tropic Env 
proteins gplZ@-gp41 with an ED,,, of -1 nh4 in the cell 
fusion assay using HeLa-CD4-CCRS-LTRI,ncZ and HeLa- 
En~m.A cell lines (L.P., unpublished observations). In con- 
trast, chemically synthesized RANTES with an unmodified 
covalent structure had an EDs,, of> 100 r&l in the same 
assay. These results are consistent with the observations 
reported using recombinant RANTES and the recombi- 
nant-derived semisynthetic AOP-RANTES [ 151. 
Crystal structure of AOP-RANTES 
AOP-RANTES prepared by total chemical synthesis was 
crystallized using the hanging drop method by ammo- 
nium-sulfate precipitation from a pH 4.5 solution. Small, 
high-quality crystals were obtained. 0The structure of 
AOP-RANTES was determined at 1.6A resolution, using 
data collected with synchrotron radiation on beamline 
X9B at the National Synchrotron Light Source (NSLS), 
Brookhaven National Laboratory. Phases were obtained by 
molecular replacement using the structure of Met-RANTES 
(D.H. and J.L., unpublished observations). The positions 
for all atoms could be defined by electron density, except 
for the sidechain of Lys45 in monomer B, which has been 
modeled in two alternate conformations. The amino termi- 
nus, from the AOP moiety to residue Thr7, is clearly 
defined (Figure 4) and packs against the noncrystallograph- 
ically related monomer, with the AOP group bound within 
a hydrophobic depression on the surface (Figure 5). The 
fold of the AOP-RANTES monomer is similar to that of 
other CC and CXC monomers, forming a three-stranded 
antiparallel p sheet flanked by a carboxy-terminal a helix 
(Figure 6). A short fi sheet (pl) is formed between the 
monomers from residues Thr8 to CyslO, finishing with a 
long loop between Cysl 1 and Pro20 that stretches over the 
molecule. After a short 3,,, helix (ArgZl-His23), the main 
p sheet is formed by IleZ4-TyrZ9 (PZ), Val39-Thr43 (83) 
and Gln48-Ala51 @4). Residues Lys%-Glu66 form the 
carboxy-terminal a helix (al), with residues Met67 and 
Ser68 in an extended conformation. The loop between @ 
and p3 contains a type III reverse turn (Ser31-Cys34); the 
loop between p3 and p4, a distorted type I reverse turn 
(Thr43-Asn46); and the loop between p4 and al. a type I 
Figure 4 
1 Chemistw & Biolwy 
Electron density contoured at 1.2 o surrounding the AOP group, 
Pro2 and ‘Tyr3. The figure was made using MOLSCRIPT 1391 and 
Raster3D [40]. 
reverse turn (As&!-Lys55). Secondary structure elements 
were defined using the program DSSP [24]. 
The contacts between monomers that are involved in 
creating the dimer are minimal. Aside from the antiparal- 
lel p sheet formed by residues Thr8-CyslO and the 
AOP-linked amino termini, hydrogen bonds are formed 
between SerS(0) and CysSO’(N), Asp6(N) and Gln48’(0) 
and Thr;‘(OGl) and Gln#‘(OEl). Also, there are several 
Figure 5 - 
Close-up of ihe AOP 1 moiety. The AOP group contacts the 
noncrystallographically related monomer at a hydrophobic depression 
formed between the phenolic ring of Tyr14, the backbone atoms of 
Ala1 3 and Phe12, the CDs of Cysl 1, Asn36 and Pro37 and the Q of 
Thr30. The figure was made using MOLSCRlPT [39] and Raster3D [40]. 
48 Chemistry & Biology 1999. Vol 6 No 1 
Figure 6 
al' 
Overall structure of AOP-RANTES. The 
dimer is shown here as it appears in the 
asymmetric unit of the crystal structure. 
Sec:ondary-structure elements as labeled 
were determined using the program DSSP 
[241. The figure was made using the program 
RIBBONS [411. 
solvent-mediated hydrogen-bond bridges across the dimer 
interface, connecting the loops between p2 and p3. Because 
of loose packing between the monomers, a gap between 
Phel2 and Phe12’ is filled with a solvent molecule that 
alternates between two positions in the crystal. 
The conformation of the AOP group, Pro2 and ‘ryr3 is 
slightly different in the two monomers. This difference can 
be explained by a crystal contact in one of the monomers. 
There are contacts between the peptide ProZ-Tyr3 of 
monomer B and the symmetry-related ring of Tyr29, which 
cause the amino terminus co push closer to the protein. 
There are no contacts between the amino terminus of 
monomer A and cryscdl~ographicd~~y related molecules, 
however. Comparison of the amino termini from both 
monomers shows the amino terminus of monomer A to be 
better resolved and more highly ordered than monomer B, 
with clearer density and lower temperature factors. The 
crystal contacts Iof monomer B seem to disrupt the close 
packing of the AOP group, and the conformation of the AOP 
group in monomer A suggests an unbiased conformadon. 
Comparison of AOP-RANTES crystal structure to RANTES 
NMR structures 
There is very little difference in the secondary structure 
between the crystal structure of AOP-RANTES, described 
here and the NMR structures of native IL4NTES [l&19]. 
aside from assignment discrepancies at the ends of sec- 
ondary structure elements. The root mean square deviation 
(rmsd) values for superpositioning the backbone atoms of 
AOP-RANTES residues lo-68 onto the equivalent atoms of 
the 1RTO [18] and 1HRJ [19] structures are 1.0 and 1.3 A, 
respectively. The amino terminus (residues l-10) moves 
significantly in the overlay of AOP-RANTES on these 
NMR structures, however (Figure 7). In contrast to the 
RANTES NMR structures. in which the conformation of 
the first five residues was not determined at all and several 
carboxy-.terminal residues are extensively disordered, the 
AOP grllup, Pro2 and Tyr.3 are seen quite clearly in the 
AOP-RAILTES crystal structure (Figure 4). The amino 
termini wrap around the neighboring monomer, rather than 
being more exposed to the solvent. The conformation of the 
disulfide bridge between CyslO and Cys.M is different for 
the AOP-R4NTES structure; although this bridge makes a 
left-handed turn in all three structures, it is slightly dis- 
torted in the 1RTO structure (181 and very distorted in 
the 1HRJ model [lc)]. Because of the movement of CyslO, 
changes between the A’AIR and crystal structures are 
noticeable in the loop between 8.2 and J33. probably due to 
the disulfide link between Cys10 and CysM. There are 
also several flipped peptide bonds between residues 31 and 
36. Although the hydroxyl group of Thr.30 is hydrogen 
bonded to Ala3Y(N) in the NMR structures, the donor 
hydroxyl oxygen is replaced by the carbonyl oxygen of 
Thr30 in the crystal structures. This replacement buries the 
sidechain into the protein and allows the loop to pack more 
tightly against the protein. The differences between the 
NMR models and the crystal structure might be due, in part, 
to the relatively small amount of information afforded by the 
solution spectroscopic protein structure determinations, 
resulting in insufficient geometric constraints; the flexibility 
of the protein might also play a role in these differences. 
The largest differences art: found in the dimer inten%ce. 
The sparse contacts between the monomers seem to allow 
the dimer to flex, as seen in a comparison of the AOP- 
RANTES dimer-wi.th the I%fR structures of RANTES. 
This flexibility seems to be inherent to the molecule. 
because much larger differences between quaternary struc- 
tures of RANTES were r’eporred in the NMR models 
[1X,19] and in the structures of a related CC chemokine, 
MCP-1, obserlred in differe.nt crystal forms [ZS]. Although 
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the two monomers are linked through a short p sheet 
by residues T1~r8-Cys10, the relative orientations of the 
monomers to each other are quite different. The dimeric 
structure of AOP-RANTES is more compact than the 
NMR structure, as reflected in the total buried surfaces. 
AOP-R4NTES buries 20% of the total monomeric solvent- 
accessible surface on dimerization (monomer A = 512.5 AZ, 
monomer B = 4917 AZ, dimer = 8081 A2), whereas the NMR 
structures bury only 14% in the 1RTO mode1 (monomer 
A = 5314 w2, monomer B = 5316 AZ. dimer = 9186 AZ) [18] 
and 16% in the 1HRJ model (monomer A = 5451 A?, 
monomer B = 5429 AZ. dimcr = 9142 AZ) [19]. The differ- 
ence in the buried surface area between AOP-RAN’I’ES 
and RANTES is due mainly to the tight fit between the 
Pro2 and AOP groups wrapped around the surface of the 
neighboring monomer. Although it is questionable whether 
the monomer or dimer is the active form of the molecule, it 
is known that at physiological pH RANTES can form 
higher-order oligomers at high concentration [18] and in the 
presence of glycosaminoglycans [26]. 
It has been shown in many studies that the amino terminus 
of RANTES and other CC chemokines plays a crucial role 
in the binding to and activation of chemokine receptors. 
Truncations and alterations of the amino terminus give rise 
to chemokine antagonists of various potency [27-291, as well 
as inhibiting the infection of primary human macrophages 
by HIV-1 in VLW [lS]. Yet the exact role of the AOP group 
in this effect is not known, but could be due to an increase 
of affinity for the receptor, a decrease in receptor activa- 
tion and/or an inhibition of receptor recycling [ 14,301; all of 
these effects would arise from some unknown interaction 
between the chemokine and the receptor. Another possi- 
bility includes a change in transfer to the cell surface as 
mediated by glycosaminoglycans [ 261, although the binding 
to glycosaminoglycans has been shown to be mediated pri- 
marily by positively charged residues on a surface Lr from 
the amino terminus [Jl]. 
The attachment of the AOP moiety to the amino termi- 
nus alters the chemical nature and surface features of the 
RANTES molecule; this could give rise to any of the 
possible scenarios described above. The crystal structure 
of AOP-RANTES shows the amino terminus to be clearly 
defined and bound to the surface as compared with the 
disordered amino terminus of native RANTES. The 
sequestration of the amino terminus from solution to the 
surface might therefore disallow specific interactions 
with chemokine receptors. Alternatively, the presence of 
the AOP group might disturb the monomer/dimer equi- 
librium, which might or might not play a role in receptor 
binding and activation [32]. Without a complete under- 
standing of chemokine receptor activation, it is difficult 
to state the reasons for the antagonist properties of AOP- 
RAN’TES. Further studies of other RANTES derivatives 
would be helpful in evaluating different hypotheses. 
Figure 7 
Overlay of ihe crystal structure Iof AOP-RANTES on the two available 
NMR structures of native, recombinant RANTES. As can be seen, the 
monomer-monomer orientation in the dimer is very different between 
the crystal structures and the NMR structures. AOP-RANTES is shown 
in blue, 1 RTO 1181 in green, and 1 HRJ 1191 in red. This figure was 
made using RIBBONS [41]. 
The availability of reliable synthetic methods should 
facilitate these investigations greatly. 
Significiance 
In this pajper, we have described a convenient total chemi- 
cal synthesis of high-purity AOP-FUNTESS on a multi- 
milligram scale. These large amounts of protein are 
essential to fully characterize the properties of this potent 
anti-HIV chemokine derivative in animal models and 
are necessary for structural analysis using lH nuclear 
magnetic resonance (NMR) and X-ray crystallography. 
The synthetic polypeptide folded to give a homogeneous 
protein species. The synthetic protein crystallized and dif- 
fracted X-rays to high resolution (better than 1.6 A>. The 
secondary structure of synthetic AOP-RANTES is very 
similar to that of recombinant RANTES, as shown by 
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comparison of the crystal structure with NMR structures. Table 1 
Robust synthetic access to modified forms of RANTES 
will enable the systematic application of the principles of 
Statistics for data collection and model refinement. 
___ 
medicinal chemistry to refining the properties of this Wavelength (!I) 0.98 
important protein molecule. Such refinement will be of Resolutiorl (A) 20-l .6 
great value in the search for improved CCRS receptor Reflections (measured/unique) 
antagonists and will facilitate the development of agents to i 
749W;W 
56.307 A 
block HIV-l entry into peripheral blood cells, the primary 
infective step in AIDS. 
c 
Space group 
Completeness 
94.030 A 
p21212, 
Materials and methods 
Synthesis of the aminooxypentane-glyoxai oxime 1 
Aminooxypentane TFA salt (550 mg, 2.53 mmol), glyoxylic acid monohy 
drate (210 mg, 2.28 mmol) and pyridine (410 ~1, 5.06 mmol) in methanol 
(10 ml) were heated under reflux for 2 h. The volatiles were removed in 
vacua and the resulting oil was extracted with ethyl acetate. Combined 
extractions were washed with 10% citric acid and water, then dried in 
the presence of sodium sulfate. The volatiles were removed in ~acuo to 
give oxime 1 as a co~lorless solid. 
Synthesis of the peptide segment 
Peptides were synthesized using highly optimized Boc SPPS protocols 
[22J. Boc amino acids were used with the following sidechain protec- 
tion: Arg(Tosyl), Asn(Xanthyl), Asp(OcHxl), Cys(4MeBzl), Glu(OcHxl), 
His(DNP), Lys(2CIZI, Ser(Bzl), Thr(Bzl), Trp(formyl) and Tyr(BrZ). AOP- 
RANTES (2-33)alhioester was synthesized on a thioester-generating 
resin (21) with compound 1 coupled as the preactivated HOAt ester for 
5 h at room temperature as the last step in the synthesis. RANTES 
(34-68) was synthesized on a Boc-Ser(Bzl)OCH,-Pam resin. After com- 
pletion of the chain assembly, the peptides were simultaneously cleaved 
and deprotected from the resin by using anhydrous hydrogen fluoride 
containing 5% pcresol for 1 h at 0°C. The crude peptides were purified 
on a C4 RP-HPLC column (linear gradient of 15-55% acetonitrile and 
H,O containing O.l%TFA for 53 min). Fractions were analyzed by 
ESI-MS, and those of the correct mass were pooled and lyophilized 
[AOP-RANTES (2-3#3)-a-thioester: observed mass, 4178.1 + 0.77 Da; 
calculated mass, 4178.6 Da (average isotope composition); RANTES 
(34-68): observed mass, 4098.0 i 0.50 Da; calculated mass, 4097.8 Da 
(average isotope composition)]. 
Synthesis of AOP. RANTES (2-68)~[(SH)J 
RANTES (34-68) (111 mg, 27 pmol) was dissolved in 6 M GuHCI, 
200 mM phosphate (pH 7) containing 0.5% thiophenol and ligated 
with AOP-RANTES (2-33)-a-thioester (104 mg, 25 vmol) at a final 
peptide concentration of 20 mg ml-l. The ligation reaction was 
allowed to proceed to completion with stirring for 16 h. Excess P-mer- 
captoethanol was added to the ligation solution to reduce partially oxi- 
dized ligated product prior to purification on a C4 RP-HPLC column 
(linear gradient of 20-60% acetonitrile and H,O containing 0.1% TFA 
for 60 min). Fractions were analyzed by ESI-MS, and those of the 
correct mass were pooled and lyophilized [AOP-RANTES (2-68)- 
[(SH),]: observed mass, 7904.5 f 0.4 Da; calculated mass, 7905.2 
Da (average isotope composition)]. 
Folding 
AOP-RANTES (2-68)-[(SH),] was dissolved at 1 mg ml-’ in 2 M 
GuHCI, 100 mM Tris (pH 8) containing 8 mM cysteine and 1 mM cystine. 
After gentle stirring overnight, the protein solution was purified on a C4 
RP-HPLC column (linear gradient of lo-50% acetonitrile and H,O 
containing 0.1% TF/\ for 60 min). Fractions were analyzed using 
ESI-MS, and those of the correct mass were pooled and lyophilized 
[AOP-RANTES: observed mass, 7901.2 + 0.6 Da; calculated mass, 
7901.2 Da (average isotope composition)]. 
NMR Measurements 
For NMR experiments, 5 mg of protein was dissolved in 0.54 ml of 
25 mM sodium acetate buffer (pH 3.7) containing 60 (11 of D,O. 
Experiments were conducted at 37’C. To assess the conformational 
(over&/highest resolution bin) 
*L/e (overall/highest resolution bin) 
I/o(l) (overall/highest resolution bin) 
+R factor/free R factor 
*rmsd: bonds (A) 
rmsd: angles (degrees) 
Average temp. factor 
(protein atoms/all atoms, A ‘2 ) 
Number of residues 
Number of solvent/S0,2- molecules 
99.8/l 00.0 (1.60-l .66 8) 
0.043IO.196 
31.817.5 
0.167/0.241 
0.008 
1.4 
19.53123.75 
134 
21514 
*L/e = XII,-<I>J/Z<I>. +R factor = ~){IF,J-yF,J)I/ZIF,J; free 
R factor = I:uErl((Fo(h)l-klF,(h)il(/I;(,~ ~~lF,(h)(, where T  represents a 
test set of reflections not used in the refinement. *rmsd, root mean 
square deviation. 
homogeneity of the synthesized protein, a TOCSY experiment was 
performed [using the DIPSI- sequence 1331, with water suppression 
by the double pulse field gradient spin echo technique [341. The 
mixing time was 40 ms; acquisition times were 70 ms in the first 
dimension ,and 170 ms in the second dimension. For each of 512 
complex increments, 64 scans were collected giving a total experi- 
mental time of 27 h. Data were processed using macros written 
within the program FELIX95 (MSI Inc., San Diego, CA). Assignments 
were made by analyzing the TOCSY spectrum in combination with a 
proton-proton nuclear Overhauser effect spectrum (data not shown). 
A full assignment and interpretation of the data are underway (P.N.B., 
H.M., D.A.T and J.W., unpublished observations). 
Crystallizaiion and structure determination of AOP-RANTES 
The lyophilized AOP-RANTES !sample was resuspended in 10 mM 
sodium acetate (pH 4.6) at a concentration of 15 mg ml-‘. 2 1.11 of this 
protein solution was mixed with 2~1 of precipitant IO.1 M ammonium 
sulfate, 225 mM sodium succinate (pH 4.0), 275 mM P-(N-morpholino)- 
ethanesulfonic acid (pH 6.0), 15% ethanol]; due to the hydrophobicity of 
AOP-RANTES, it was further diluted to 20 ~1 with 16 1.~1 H,O. This solu- 
tion was then suspended over 1 ml of the same precipitant and left to 
equilibrate for 3-4 weeks at 20°C 
Single crystals grew only to a small size (0.1 x 0.1 x 0.05 mm3), as 
larger crystala became intertwined and were thus unusable. For diffrac- 
tion experiments, the crystals were mounted on small fiber loops and 
rapidly cooled in a 1OOK nitrogen stream, after washing the crystals 
briefly in the precipitant solution described above (with the addition of 
15% glycerol as a cryoprotectant). These small crystals diffracted to 
only 2.5 A on a rotating anode X-ray source (Rigaku RU200 generator 
with a MAR345 image plate), with exposure at a rate of 20 min/degree 
oscillation. Diffraction extending beyond 1.6 A, however, was obtained 
using synchrotron radiation (beamline X9B, NSLS), where a complete 
data set was collected from a single crystal. The data were collected 
using 1” oscillations, and individual reflections were integrated and 
scaled using HKL2000 135). Statistics for the data are given in Table 1. 
The phases were obtained by molecular replacement using the X-ray 
structure of Met-RANTES (D.H. and J.L., unpublished observations). Ten 
percent of the structure amplitudes was then partitioned into a test set to 
monitor refinement using cross-validation [361. These data were not used 
during the refinement. After four rounds of refinement using X-PLOR 
Research Paper Synthesis and crystal structure of AOP-RANTES Wilken et a/. 51 
[37], the R factor was 0.209 for data in the shell 8-2.4 A. The refinement 
was expanded to 1.6A resolution, and after seven rounds of refinement 
and model building, two AOP groups were introduced, and the model 
included four sulfates, all residues (Pro2-Ser68), and 148 solvents, 
yielding an R factor of 0.235. After three more rounds, which included 
both X-PLOR and SHELX-97 1381, the final R factor wasOO.l 67 and the 
free R factor was 0.241 for the resolution range 20-l .6A. Statistics for 
the refinement and the final model are given in Table 1. The atomic coor- 
dinates and structure factors for AOP-RANTES have been deposited 
with the Protein Data Bank (accession number for the coordinates 1 b3a 
and rl b3asf for experimental structure factors). 
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